HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program...
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for...
HOOKIPA Pharma (NASDAQ: HOOK) Enters into Collaboration Deal with Roche to Develop HB-700 For KRAS-Mutated Cancers
HOOKIPA Pharma, Inc. (NASDAQ: HOOK) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development
HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
HB-200 Phase 1 data presented at ASCO met all endpoints in heavily pre-treated head and neck cancer patients; Phase 2 study underwayUS Food and Drug...